SEARCH

SEARCH BY CITATION

References

  • Bachman E, Feng R, Travison T, Li M, Olbina G, Ostland V et al. (2010) Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab 95, 47434747.
  • Ballal SH, Domoto DT, Polack DC, Marciulonis P & Martin KJ. (1991) Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17, 2933.
  • Basaria S & Dobs AS. (1999) Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 15, 131142.
  • Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS & Montori VM. (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91, 19952010.
  • Bhatia V, Chaudhuri A, Tomar R, Dhindsa S, Ghanim H & Dandona P. (2006) Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 29, 22892294.
  • Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC & Bremner WJ . (2006) Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis 47, 251262.
  • Calof O, Singh AB, Lee ML, Urban RJ, Kenny AM, Tenover JL & Bhasin S. (2005) Adverse events associated with testosterone supplementation of older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Med Sci. 60, 14511457.
  • Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger O, Ozgurtas T, Yenicesu M, Lindholm B & Stenvinkel P. (2011). Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 26, 184190.
  • Chateauvieux S, Grigorakaki C, Morceau F, Dicato M & Diederich M. (2011) Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol 82, 12911303.
  • Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB & Bhasin S. (2008) Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 93, 914919.
  • Dunlop WP, Cortina JM, Vaslow JB & Burke MJ. (1996) Meta-analysis of experiments with matched groups or repeated measures designs. Psychol Methods 1, 170177.
  • Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ et al. (2010) Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95, 25602675.
  • Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, Valenti G, Ershler WB, Guralnik JM & Longo DL. (2006) Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 166, 13801388.
  • Grossmann M, Panagiotopolous S, Sharpe K, MacIsaac RJ, Clarke S, Zajac JD, Jerums G & Thomas MC. (2009) Low testosterone and anemia in men with type 2 diabetes. Clin Endocrinol (Oxf). 70, 547553.
  • Ip FF, di Pierro I, Brown R, Cunningham I, Handelsman DJ & Liu PY. (2010) Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol 162, 385390.
  • Jockenhovel F, Vogel E, Reinhardt W & Reinwein D. (1997) Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res. 2, 293298.
  • Malgor LA, Valsecia M, Verges E & De Markowsky EE. (1968) Blockade of the in vitro effects of testosterone and erythropoietin on Cfu-E and Bfu-E proliferation by pretreatment of the donor rats with cyproterone and flutamide. Acta Physiol Pharmacol Ther Latinoam 48, 99105.
  • Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, Eastell R, Wu F & Ross RJ. (2006) Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl 29, 381391.
  • Molinari PF. (1982) Erythropoietic mechanisms of androgens: a critical review and clinical implications. Haematologica 67, 442460.
  • Moriyama Y & Fisher JW. (1975) Effects of testosterone and erythropoietin on erythroid colony formation in human bone marrow cultures. Blood 45, 665670.
  • Naughton CA, Duppong LM, Forbes KD & Sehgal I. (2003) Stability of multidose preserved formulation epoetin alfa in syringes for three and six weeks. Am J Health Syst Pharm 1:60, 464468.
  • Pelekanou V, Notas G, Sanidas E, Tsapis A, Castanas E & Kampa M. (2010) Testosterone membrane-initiated action in breast cancer cells: interaction with the androgen signaling pathway and EPOR. Mol Oncol 4, 135149.
  • Rishpon-Meyerstein N, Kilbridge T, Simone J & Fried W. (1968) The effect of testosterone on erythropoietin levels in anemic patients. Blood 31, 453460.
  • Shahani S, Braga-Basaria M, Maggio M & Basaria S. (2009) Androgens and erythropoiesis: past and present. J Endocrinol Invest 32, 704716. Review.
  • Shahidi NT. (1973) Androgens and erythropoiesis. N Engl J Med 289, 7280.
  • Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH et al. (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84, 19661972.
  • Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T & Bachand R. (2003) AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88, 26732681.
  • Viallard JF, Marit G, Mercie P, Leng B, Reiffers J & Pellegrin JL. (2000) Polycythaemia as a complication of transdermal testosterone therapy. Br J Haematol 110, 237238.
  • Woodman R, Ferrucci L & Guralnik J. (2005) Anemia in older adults. Curr Opin Hematol 2005; 12, 123128. Review.